Pages

Take a look here

Saturday, December 25, 2010

Chronic renal allograft dysfunction

This month's Kidney International has a special extra edition on Chronic renal allograft dysfunction.
This supplement has >10 articles that highlights latest development in transplantation on pathogenetic mechanisms of T and B cells in Chronic rejection, IF/TA and then few chapters on fibrosis and genomic studies.
Risk factors, infections and immune monitoring are also discussed.

Few of them are linked below:
http://www.ncbi.nlm.nih.gov/pubmed
http://www.ncbi.nlm.nih.gov/pubmed/21116312
http://www.ncbi.nlm.nih.gov/pubmed/21116316

Thursday, December 23, 2010

TOPIC DISCUSSION: Hypokalemic Nephropathy

Yes... Hypokalemia that is chronic can lead to decrease in GFR and nephropathy. How so?
Also known as kaliopenic nephropathy
1. Hypokalemia can lead to a renal concentrating defect leading to polyuria and polydipsia- DI
2. Chronic tubular damage can occur as a result and lead to proximal tubular damage as well
3. Tubular interstitial disease develops
4. Proteinuria can be seen
5. Renal cysts can be noted
6. There is also impairment of  renal angiogenesis, evidenced by progressive capillary loss, reduced endothelial cell proliferation, and loss of VEGF expression in one study.
7. Histologically:- tubular atrophy, interstitial infiltration of macrophages, and fibrosis
Ref:
http://www.ncbi.nlm.nih.gov/pubmed/18178802
http://www.ncbi.nlm.nih.gov/pubmed/17928827
http://www.ncbi.nlm.nih.gov/pubmed/20828906

Tuesday, December 21, 2010

CMV in solid Organ transplantation!

CMV infections are fairly common in solid organ transplantations.  A nice review in Nature Review Nephrology this month highlights prophylaxis treatment, active treatment and serology testing. What I found very useful wa a table on dosage recommendations for ganciclovir and valganciclovir in varied renal function states. 
A nice section on anti viral resistance also reveals some important data on use of foscarnet and when there is UL97 mutations.  These strains usually have ganciclovir resistance.  The UL54 strain mutation can have resistance to even foscarnet and cidofivir.  The advent of commercially available genotyping allows for rapid results of UL97 or 54 and allow for personalized treatment of CMV viremia or disease.  
Resistant CMV guidelines
1. Increase dose of ganciclovir 
2. Change to foscarnet with or without continued ganciclovir
3. Change to Cidofovir only if pol mutations are not present otherwise it cross reacts with ganciclovir resistance.
4. leflunomide has been tried in few cases.
5. CMV immunoglobulin (IVIG) as a last resort and if there is organ damage happening.

Check it out

Monday, December 20, 2010

CLINICAL CASE 30, ANSWERS AND SUMMARY

Tenofovir can cause proximal tubular damage? Recent data show it to damage what part of the cell?

Nucleas 2%

Mitochondria 71%

MRP-2 Channel 17%

NK ATPase pump 7%

The HIV drug Tenofovir, as we all know , can be nephrotoxic. Proximal tubular damage is what we usually see with full blown Fanconi syndrome as well in some cases.  What the organic anion drug do in the proximal tubule cell?  It is delivered to the basolateral membrane of the proximal tubule cell and its transported into the cell by the organic anion transporter OAT-1.  Once it enters the cell, the drug is secreted into the urinary space via MRP-2 and MRP-4 ( multidrug resistance protein transporters).  The damage we see with this drug is via direct mitochondrial DNA depletion and damage done by the drug within the cell.  Disturbances in the secretory pathway ( increased OAT-1 or decreased MRP efflux) can lead to increased drug levels in the cell and ultimate mitochondrial damage.  MRP-2 is a good answer but mitochondria is the best answer as the damage really is via mitrocondria that leads to the final proximal cell tubulopathy. 
This has been shown in EM findings or ultrastructual findings that show eisonophilic intracytoplasmic inclusions within the proximal tubular epithelial cells, that are the giant mitochondria seen usually.  The mitochondria have abnormal cristae and hence don't function.  
This ultimately leads to strange shaped and large shaped mitochondria that are non functional and tenofovir induced toxicity. 
A nice reference from KI is listed below:

Sunday, December 19, 2010

In the NEWS: Angiopoietin like 4 , a glycoprotein that might change the face of glomerular disease.

A recent study published in Nature Medicine reveals some very interesting findings. The researchers in Alabama showed that glomerular expression of angiopoietin-like-4 (Angptl4), a secreted glycoprotein, is glucocorticoid sensitive and is highly upregulated in the serum and in podocytes in experimental models of minimal change disease and in the human disease. Podocyte-specific transgenic overexpression of Angptl4 (NPHS2-Angptl4) in rats induced nephrotic-range, and selective, proteinuria (over 500-fold increase in albuminuria), loss of glomerular basement membrane (GBM) charge and foot process effacement, whereas transgenic expression specifically in the adipose tissue (aP2-Angptl4) resulted in increased circulating Angptl4, but no proteinuria. Mice with no Angptl4 had no proteinuria.  
This is exciting in many ways: This might suggest that this specific protein might be the type of nephrotic syndrome that responds to steroids, so if you have elevations of this protein in your urine or blood you have a certain nephrotic syndrome that will respond to steroids and decrease proteinuria. Lets see what this pans out in human studies.  Great work by the scientists at Alabama on this breakthrough discovery. Check out the link below.

http://www.ncbi.nlm.nih.gov/pubmed/21151138

Saturday, December 18, 2010

Health Care Law Blog: AMA Issues New Policy To Guide Physicians’ Use of ...

Health Care Law Blog: AMA Issues New Policy To Guide Physicians’ Use of ...: "Today the American Medical Association announced that it has adopted and issued a new policy offering guidance to physicians on the use of s..."

Genetic Nephropathies and Kidney Transplantation

A recent article in Nature Review Nephrology reviews the diseases we always get worried if a living donor can be used.
This review outlines the does and don't of hereditary nephropathies and donor evaluation of kidney transplantation. A table in the articles nicely summarizes the disease entity and if the living related donation would be appropriate.
In Finnish type Congenital Nephrotic syndrome, NPHS2 FSGS, NPHS3 FSGS, Pierson Syndrome, Schimke's immunoosseous dystrophy, nephronophthisis, cystinosis and ARPKD and alport syndrome:- it is ok to use living related donation in transplantation.  In Primary Hyperoxaluria and Atypical HUS, one has to be careful in selecting the donor from a living relative.
In general AR type of diseases, the donor can be a relative and most of the time its not a problem. Autosomal Dominant diseases is always a concern. We come across this most in ADPKD and the donor evaluation in that case is so strict and needs careful screening if its a relative.  Atypical HUS should not receive a kidney transplantation from a living donor because it is a high risk for disease recurrence and graft loss.

Ref:
http://www.ncbi.nlm.nih.gov/pubmed/20877305

Friday, December 17, 2010

Medicine for residents: a little step towards cost effectiveness - renal ...

Medicine for residents: a little step towards cost effectiveness - renal ...: "A renal ultrasound is a very good study that gives a lot of useful information for a lot of kidney diseases. Especially...in Acute Kidney in..."

Thursday, December 16, 2010

IN THE NEWS- Article on Online Blogging of Conferences

Check out first of its kind article on "online blogging" of nephrology conferences powered by Nephrology on Demand, Pediatric Nephrology.com and Nephronpower.com.
A treat for all bloggers in Nephrology. Its published in the recent edition of Kidney International.

Ref: http://www.nature.com/ki/journal/v78/n12/abs/ki2010395a.html

Wednesday, December 15, 2010

Tuesday, December 14, 2010

TOPIC DISCUSSION: Anesthetics and Kidney Disease

Do Anesthetic agents cause Renal Disease?
A recent discussion in a nephrology forum this above question was asked. Evidence on this is scant. On literature review, few cases reports found in 1960-80s and none after that. Perhaps we have not been using these agents anymore.  Some of the older agents might have cause renal disease.  In animal experiments, kidney damage has been reported after low level exposure of halothane.  Few case reports exist of methoxyflurane causing renal dysfunction.  There was a retrospective cohort study and it reported a higher frequency of kidney disease among exposed persons especially women ( in 1968).  Moderate to temporary effect on kidney function has been shown  in patients who got methoxyflurane.  Rats were subjected to chronic exposure to low levels of halothane (10 and 500 ppm for 8 and 4 weeks, respectively). Kidney histology showed proximal tubular changes and mitochondrial injury.
In the 1960s, the widespread use of the inhalational anaesthetic methoxyflurane was associated with a significant occurrence of postoperative renal dysfunction. This was attributed to hepatic biotransformation of methoxyflurane and subsequent release of inorganic fluoride ions into the circulation. It was found that this was more due to the drug containing massive amounts of fluoride and this was all fluoride toxicity. Nowadays, fluoride-related toxicity has been observed neither in animal nor in clinical studies, including prolonged administration and patients with pre-existing renal disease.

Reference:

Friday, December 10, 2010

Concept Map of Hypomagnesemia



A brief overview of Hypomagnesemia using a concept map model
If not complete, help me complete it!

http://www.ncbi.nlm.nih.gov/pubmed/10405219

Quiz 9 Answers

Which drug is paired incorrectly with the target molecule?
Rituximab -- CD20
Alemtuzumab -- CD52
Belatacept -- CD198
Belimumab --- TNFSF13B
Atacicept ---TACI-Ig

The correct answer is Belatacept CD198, that is incorrect pairing. Most of you got it right.
We all are familiar with Rituximab which is a B cell antagonist and since all B cells besides plasma cells are CD20 Positive, its an anti CD20. Alemtuzumab(campath) targets cd52 a protein present on the surface of mature lymphocytes. Atacicept(TACI-Ig) is a human recombinant fusion protein that comprises the binding portion of a receptor for both BLyS (B-Lymphocyte Stimulator) and APRIL (A PRoliferation-Inducing Ligand), two cytokines that have been identified as important regulators of B-cell maturation, function and survival. Atacicept has shown selective effects on cells of the B-cell lineage, acting on mature B cells and blocking plasma cells and late stages of B-cell development while sparing B-cell progenitors and memory cells. The efficacy of atacicept in animal models of autoimmune disease and the biological activity of atacicept in patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) has been demonstrated. The selective inhibitor of T-cell costimulation, belatacept, blocks CD28-mediated T-cell activation by binding CD80 and CD86 on antigen-presenting cells. Understanding the extent to which belatacept binds to its targets in patients may enable correlation of belatacept exposure to receptor saturation as a pharmacodynamic measure of costimulation blockade.
Belimumab (registered name Benlysta previously known as LymphoStat-B), is a fully human monoclonal antibody that specifically recognizes and inhibits the biological activity of B-Lymphocyte stimulator (BLyS), also known as B cell activation factor of the TNF family (BAFF).

Tuesday, December 7, 2010

IN THE NEWS- Meta-analysis in Nephrology

A recent article in Kidney International reviews the role of meta analysis in Nephrology world. Based on the survey this group did in NYC area, most physicians viewed meta analysis in nephrology useful and influenced their patient care.
What are the limitations of meta analyses?( from the article- refer to article for details)
1. Publication bias
2.Mixing apples and oranges
3. Garbage In, Garbage Out
4. Outcome selection bias
5. Patient exclusion bias
6. Truncated study bias
7. data collection errors
What are the strengths  of meta analyses?
1. Power
2. Highlights areas that need work
3. More transparent form of review- and not just a review article
4. Sounder bias offered
Even with all these meta analyses happening in our literature, many of our guidelines are still "opinion" based.

Ref:
http://www.ncbi.nlm.nih.gov/pubmed/20827259

Monday, December 6, 2010

TOPIC DISCUSSION: Camels and their Kidney!

Ever wondered what the camel does differently than us to survive in the hot environment? The camel does have a special kidney and a special GI tract.The camel's kidney actually can concentrate the urine more than sea water but less than a dessert rat.  Since the camel can concentrate the urine more than sea water, salty water intake won't harm the animal. Investigators have studied the  structure of the camelian kidney to discover whether or not the anatomical features necessary for producing a highly concentrated urine were present or not. The relative thickness of the medulla was calculated in the camelian kidney as it has been demonstrated that this thickness has a direct relationship with the ability to produce a highly concentrated urine.  A relative thickness of the medulla is a good measure of the length of the loop of Henle which is an indicator of urine concentration. The thickness reported in camels was 7.89 in comparison to the value of 8.5 in kangaroo rats, much more than humans.
Also, what happens if you haven't drunk water in 5 days and all of a sudden you re hydrate. A dehydrated camel can replace water within minutes of drinking, and some of this water is quickly absorbed into the bloodstream. With water in the bloodstream, ADH declines and the kidney will return to normal renal function within 30 minutes of drinking. Not only does the camel adopt to scarce water but the kidney can also adopt to rapid dehydration and not lead to demylination of the brain.
What are some other features this animal has to store water for long periods of time?
Another interesting part of the camel physiology is that they have 3 stomachs, acting as storage( 1.5 gallons per stomach) for the water and hence when water is not available, they can slowly replenish the system. The camel stores water in its blood stream, an interesting physiological process. Capable of losing forty percent of its body's weight before becoming distressed, it is able to go five to seven days before having to drink. The amount it drinks when water is available would cause severe problems in most animals, up to 21 gallons in about 10 minutes.The camel's mouth, stomach, and teeth have all developed to allow it to eat plants that are not palatable to other desert animals.Contrary to popular myth, the camels don't store water in their humps, its full of fat for food storage.
Some of the rodents in the dessert can actually concentrate up to 7500mOsm.
Fun things you can learn from other animals who adopt better to water problems

http://www.ncbi.nlm.nih.gov/pubmed/511770
http://www.ncbi.nlm.nih.gov/pubmed/407772
http://www.ncbi.nlm.nih.gov/pubmed/475010

Friday, December 3, 2010

Sirolimus- the Positive aspects

The same issue of KI shares another view- the positive aspects of sirolimus
As we mentioned earlier that this agent was discovered as a cancer drug and has antiproliferative properties

Recent animal data and human data have shown it to be beneficial in preventing cancer post transplant
So the benefits of this agents are:

1. Prevention of cancer, as mTOR is responsible for transcription and translation for cell growth.  Definite evidence against Kaposi, Skin cancers and renal cancers.
2. Increase in T regs
3. Anti viral effects - CMV, BK and EBV viral infections ( still not sure- conflicting data)
4. Tolerance inducing potential
5. Control of fibrotic process - conflicting data when compared to CNI alone

Ref:
http://www.ncbi.nlm.nih.gov/pubmed/20981120

Thursday, December 2, 2010

Nephsap review: Fluids Electrolytes

Another interesting Nephsap teaching point by a question was an under recognized cause of acquired apparent mineralcoritcoid access.
Liver cirrhotic patients with elevated bilirubins and sickle cell crisis patients who have elevated bilirubins have this happen to them.  When total bilirubin levels are very high, it is hypothesized that worsening cholestasis led to greater bile acid inhibition of 11B - HSDH type II in the distal nephron and this allows for K wasting via cortisol mediation and HTN as well.
Case reports have been reported in liver cirrhosis and sickle cell crisis patients?
Wonder if we see this or its noticed in Post BMT - VOD syndrome?